search
Back to results

The Role of Real-time Appearance of Lymphatic Flow in Lymphatic Mapping in Endometrial Cancer

Primary Purpose

Sentinel Lymph Node

Status
Recruiting
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
indocyanine green
Sponsored by
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Sentinel Lymph Node focused on measuring Endometrial cancer, Sentinel lymph node, İndocyanine green, Robotic surgery, Lymphatic channel, Real-time appearance of lymphatic flowing

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Patients with clinical stage 1-2 endometrial cancer ASA 1-3 patients

Exclusion Criteria: Patients with clinical stage 3-4 endometrial cancer Patients who are not suitable for robotic surgery due to their comorbidities (such as glaucoma, COPD, asthma) ASA 4-5 patients

Sites / Locations

  • Gökhan DemirayakRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental injection

Standart injection

Arm Description

Cervical indocyanine green injections until real-time visualization of the afferent lymphatic channels bilaterally.

Cervical indocyanine green injections group

Outcomes

Primary Outcome Measures

Bilateral sentinel lymph node detection rate

Secondary Outcome Measures

Full Information

First Posted
December 29, 2021
Last Updated
December 23, 2022
Sponsor
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05191212
Brief Title
The Role of Real-time Appearance of Lymphatic Flow in Lymphatic Mapping in Endometrial Cancer
Official Title
The Role of Real-time Appearance of Lymphatic Flow in the Detection of Bilateral Sentinel Lymph Node With Fluorescence Imaging Technique in Endometrial Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 13, 2021 (Actual)
Primary Completion Date
February 8, 2023 (Anticipated)
Study Completion Date
March 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bakirkoy Dr. Sadi Konuk Research and Training Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Purpose of the study Primary treatment of clinical early stage endometrial cancer is total hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection for staging. It was stated in the National Comprehensive Cancer Network (NCCN) guideline that sentinel lymph node biopsy can be performed as an alternative to systematic lymphadenectomy, including high-risk endometrial cancer histologies (2). In a study, the rate of bilateral sentinel lymph node detection in sentinel lymph node mapping using the cervical injection technique of indocyanine green was found to be 73.3%. After re-injection of cervical indocyanine green in patients whose sentinel lymph node could not be detected, the rate of detection of bilateral sentinel lymph nodes increased to 94.5% (4). However, repeated cervical injection causes a waste of time. In our clinic, sentinel lymph node mapping method is applied using indocyanine green for lymph node dissection for staging purposes, since the robotic system has a fluorescent imaging system in patients operated with robotic surgery for endometrial cancer. In accordance with the literature, our bilateral sentinel lymph node detection rate was 75%. During cervical indocyanine green injection in our last 6 patients, the lymphatic channels in the pelvic region were followed simultaneously with the injection and indocyanine injection was performed until the channels were seen transperitoneally. Bilateral lymphatic channels were seen in all of these patients, and sentinel lymph nodes were found bilaterally in all of them. The aim of the planned study is to compare the traditional cervical indocyanine green injection and indocyanine injection until the lymphatic channels are visualized for bilateral detection of sentinel lymph nodes in patients with clinical early stage endometrial cancer. Material-Method The number of patients planned to be included in the study was calculated as 24 patients in both groups, with an alpha error value of 5% and a statistical power above 80% when the bilateral sentinel lymph node detection rate was 75% in the traditional method and 99% in the study group (SPH analytics 2021).
Detailed Description
Purpose of the study Endometrial cancer is the most common cancer of the female genital tract. In the USA, 65,620 new cases were detected in 2020, and 12,590 deaths occurred. Primary treatment of clinical early stage endometrial cancer is total hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection for staging. It was stated in the National Comprehensive Cancer Network (NCCN) guideline that sentinel lymph node biopsy can be performed as an alternative to systematic lymphadenectomy, including high-risk endometrial cancer histologies. Although dyes such as methylene blue or isosulfan blue and radioactive substances such as technetium-99 can be used in sentinel lymph node biopsy, fluorescent imaging systems using indocyanine green have recently been widely used due to high detection rates. Side-specific pelvic lymphadenectomy should be performed in the region where no sentinel lymph node can be detected. This increases the duration and difficulty of the operation and may cause morbidities such as leg edema and lymphocele. In a study, the rate of bilateral sentinel lymph node detection in sentinel lymph node mapping using the cervical injection technique of indocyanine green was found to be 73.3%. After re-injection of cervical indocyanine green in patients whose sentinel lymph node could not be detected, the rate of detection of bilateral sentinel lymph nodes increased to 94.5%. However, repeated cervical injection causes a waste of time. In investigator's clinic, sentinel lymph node mapping method is applied using indocyanine green for lymph node dissection for staging purposes, since the robotic system has a fluorescent imaging system in patients operated with robotic surgery for endometrial cancer. In accordance with the literature, the investigator's bilateral sentinel lymph node detection rate was 75%. During cervical indocyanine green injection in the last 6 patients of the investigators, the lymphatic channels in the pelvic region were followed simultaneously with the injection and indocyanine injection was performed until the channels were seen transperitoneally. Bilateral lymphatic channels were seen in all of these patients, and sentinel lymph nodes were found bilaterally in all of them. The aim of the planned study is to compare the traditional cervical indocyanine green injection and indocyanine green injection until the lymphatic channels are visualized for bilateral detection of sentinel lymph nodes in patients with clinical early stage endometrial cancer. Material-Method Among the patients who applied to the Health Sciences University, Bakırköy Dr Sadi Konuk Training and Research Hospital, Gynecological Oncology clinic due to endometrial cancer and were found to be in the clinical early stage as a result of imaging, those suitable for robotic surgery will be included in the study. An informed consent form will be signed by the patients who agree to participate in the study. Procedure: In this technic, 25 mg of indocyanine green powder dissolved in 10 cc of sterile water. A 10 mL sterile syringe is filled with 2 cc of ICG and diluted with 8 cc of sterile water, obtaining a total of 10 cc solution with a ICG final concentration of a 0,5 mg/mL. After docking of the Da Vinci Xi Surgical System (Intuitive Surgical, Sunnyvale, CA, USA), firstly, each 1 cc volume of the ICG is injected to the deep stroma (1 cm of depth) and submucosa (1 mm depth) at 9 o'clock position into the cervix by using 22-gauge spinal needle. While the injection is performing, the surgeon watches real-time appearance of ICG in the lymphatic channel transperitoneally from the console using fire-fly mode of the robotic system. If the appearance of ICG can not been observed, additional 1 cc volume of ICG is injected to the near side of first injection site of deep stroma and submucosa respectively until visualization of real-time appearance of ICG in lymphatic channel. The same procedure is performed contralateral site, at 3 o'clock position of the cervix. Then retroperitoneum is opened. Fire-fly mode of the robot is activated and sentinel nodes are removed gently All these procedures were performed by two collaborating surgeons. Demographic data of the patients such as age, parity, body-mass index, systemic diseases, tumor histology, presence of lymphovascular invasion, disease data such as tumor diameter, operation time, amount of bleeding, bilateral or unilateral detection rates of sentinel lymph nodes, if any, intraoperative and operative results such as postoperative complications, whether blood product replacement is performed, length of stay in hospital, and whether there is a need for postoperative intensive care unit will be recorded. Statistical View The number of patients planned to be included in the study was calculated as 24 patients in both groups, with an alpha error value of 5% and a statistical power above 80% when the bilateral sentinel lymph node detection rate was 75% in the traditional method and 99% in the study group (SPH analytics 2021). For continuous variables, the Mann-Whitney U test will be compared if appropriate, and for categorical variables, the frequency distribution will be compared with Chi-square or Fisher's exact test. Univariate and multivariate Cox proportional hazard ratio (HR) analyzes will be performed to identify independent prognostic factors. For all cases, a p value < 0.05 would be considered statistically significant. SPSS version 25.0 (IBM, Armonk, NY, USA) will be used for statistical analysis. Inclusion criteria Patients with clinical stage 1-2 endometrial cancer ASA 1-3 patients Exclusion criteria from the study Patients with clinical stage 3-4 endometrial cancer Patients who are not suitable for robotic surgery due to their comorbidities (such as glaucoma, COPD, asthma) ASA 4-5 patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sentinel Lymph Node
Keywords
Endometrial cancer, Sentinel lymph node, İndocyanine green, Robotic surgery, Lymphatic channel, Real-time appearance of lymphatic flowing

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental injection
Arm Type
Experimental
Arm Description
Cervical indocyanine green injections until real-time visualization of the afferent lymphatic channels bilaterally.
Arm Title
Standart injection
Arm Type
Active Comparator
Arm Description
Cervical indocyanine green injections group
Intervention Type
Procedure
Intervention Name(s)
indocyanine green
Intervention Description
Cervical indocyanine green injection for the detection of sentinel lymph node
Primary Outcome Measure Information:
Title
Bilateral sentinel lymph node detection rate
Time Frame
1 year

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with clinical stage 1-2 endometrial cancer ASA 1-3 patients Exclusion Criteria: Patients with clinical stage 3-4 endometrial cancer Patients who are not suitable for robotic surgery due to their comorbidities (such as glaucoma, COPD, asthma) ASA 4-5 patients
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gökhan Demirayak, Assoc. Prof.
Phone
+90 5323077899
Email
dmryk.g@gmail.com
Facility Information:
Facility Name
Gökhan Demirayak
City
Istanbul
ZIP/Postal Code
34147
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gökhan Demirayak, Assoc. Prof.
Phone
+905323077899
Email
dmryk.g@gmail.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
31912902
Citation
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
Results Reference
result
Citation
2- NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms Version 4.2021 -September 3, 2021 https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
Results Reference
result
PubMed Identifier
25004343
Citation
Yost KJ, Cheville AL, Al-Hilli MM, Mariani A, Barrette BA, McGree ME, Weaver AL, Dowdy SC. Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet Gynecol. 2014 Aug;124(2 Pt 1):307-315. doi: 10.1097/AOG.0000000000000372.
Results Reference
result
PubMed Identifier
33906784
Citation
Maramai M, Achilarre MT, Aloisi A, Betella I, Bogliolo S, Garbi A, Maruccio M, Quatrale C, Aletti GD, Mariani A, Colombo N, Maggioni A, Multinu F, Zanagnolo V. Cervical re-injection of indocyanine green to improve sentinel lymph node detection in endometrial cancer. Gynecol Oncol. 2021 Jul;162(1):38-42. doi: 10.1016/j.ygyno.2021.04.026. Epub 2021 Apr 24.
Results Reference
result

Learn more about this trial

The Role of Real-time Appearance of Lymphatic Flow in Lymphatic Mapping in Endometrial Cancer

We'll reach out to this number within 24 hrs